Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers at the University of Oxford led by DPAG's Professor Peter Robbins are working with clinical collaborators from NHS hospitals to carry out a new clinical drug trial aimed at treating COVID-19, funded by LifeArc. It will test a drug that could raise oxygen levels in the blood in COVID-19 patients in order to improve their chances of recovery. Raising oxygen levels is important in COVID-19, because many patients with the disease die when oxygen levels in their arterial blood fall to levels that are too low to support life.

Cartoon of pair of lungs displaying how Almitrine Bismesylate operates in Covid-19. Arrows underneath show blood flow is blocked from entering diseased right hand lung.
Cartoon by Professor Keith Dorrington
Load More